Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Amylin is a member of the calcitonin family of hormones cosecreted with insulin by pancreatic β cells. Cell culture assays suggest that amylin could affect bone formation and bone resorption, this latter function after its binding to the calcitonin receptor (CALCR). Here we show that Amylin inactivation leads to a low bone mass due to an increase in bone resorption, whereas bone formation is unaffected. In vitro, amylin inhibits fusion of mononucleated osteoclast precursors into multinucleated osteoclasts in an ERK1/2-dependent manner. Although Amylin +/− mice like Amylin-deficient mice display a low bone mass phenotype and increased bone resorption, Calcr +/− mice display a high bone mass due to an increase in bone formation. Moreover, compound heterozygote mice for Calcr and Amylin inactivation displayed bone abnormalities observed in both Calcr +/− and Amylin +/− mice, thereby ruling out that amylin uses CALCR to inhibit osteoclastogenesis in vivo. Thus, amylin is a physiological regulator of bone resorption that acts through an unidentified receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A later study found that the activity of amylin to inhibit cell fusion required the activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2) in osteoclast precursors (58).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Amylin deficiency had no effect on the regulation of food intake, body weight, or glucose metabolism in this experimental model.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“The amylin KO mice had an increased number of osteoclasts and an increase in degradation products of collagen in the urine, suggesting that the osteoporotic phenotype was a result of accelerated bone resorption (58).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to the phenotype described for the Calca-deficient mice (97), Calcr ϩ/Ϫ mice had high bone mass caused by increased bone formation without changes in bone resorption (58).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“At the age of 24 wk, both male and female amylin KO mice were osteoporotic with vertebral bone volume over tissue volume (BV/TV) ~50% lower than that of WT and trabecular and cortical bone thickness reduced.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [58]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 2×
“…studies have identified transcription factors, growth factors and their receptors, hormones and intracellular signaling molecules that affect one or the other arm of bone remodeling at the level of cell differentiation, proliferation, or function (Boyle et al., 2003; Teitelbaum and Ross, 2003).”
BackgroundParfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016 · cited 1×
“This was surprising as the calcitonin receptor (CALCR) is expressed on osteoclasts but not on osteoblasts ( Nicholson et al., 1986; Lee et al., 1995).”
BackgroundBone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,701 · cited 1×
“These latter studies have identified transcription factors, growth factors and their receptors, hormones and intracellular signaling molecules that affect one or the other arm of bone remodeling at the level of cell differentiation, proliferation, or function (Boyle et al., 2003; Teitelbaum and Ross, 2003).”
BackgroundEffects of Diabetes Mellitus on Bone Mass in Juvenile and Adult-Onset Diabetes
Levin, M. E., Boisseau, V. C., & Avioli, L. V. (1976) · New England Journal of Medicine · doi:10.1056/nejm197601292940502 · Cited by 519 · cited 1×
“Indeed, the predominant expression of amylin in pancreatic cells support the hypothesis that the low bone mass phenotype observed in Type I diabetes patients (Levin et al., 1976) may be secondary, at least in part, to the absence of amylin secretion in these patients.”
BackgroundChristopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486 · cited 2×
“, 1999, 2001); that amylin is able to bind in vitro to CALCR has raised the hypothesis that it may be a physiological ligand of CALCR on osteoclasts (Christopoulos et al., 1999).”
BackgroundNicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., & Martin, T. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112584 · Cited by 454 · cited 2×
“This was surprising as the calcitonin receptor (CALCR) is expressed on osteoclasts but not on osteoblasts (Nicholson et al., 1986; Lee et al., 1995).”
BackgroundEvidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells
Kahn, S. E., D'Alessio, D. A., Schwartz, M. W., Fujimoto, W. Y., Ensinck, J. W., Taborsky, G. J., & Porte, D. (1990) · Diabetes · doi:10.2337/diab.39.5.634 · Cited by 454 · cited 2×
“Amylin, the focus of this paper, was identified as a protein present in pancreatic cells that is cosecreted with insulin after food ingestion (Westermark et al., 1987; Kahn et al., 1990).”
BackgroundRoh, J., Chang, C. L., Bhalla, A., Klein, C., & Hsu, S. Y. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305332200 · Cited by 443
Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily
Wimalawansa, S. J. (1997) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v11.i2-3.40 · Cited by 424 · cited 2×
“Calcitonin is the founding member of a small family of polypeptide hormones that comprises of CGRP, adrenomedullin, intermedin, CALCR stimulating hormone, and amylin or islet amyloid polypeptide (Wimalawansa, 1997; Katafuchi et al., 2003; Roh et al., 2003).”
Background
Research works printed but not linked: 4
- 1998, Am. J. Physiol., 275, E694
- 1995, Endocrinology., 136, 4572, 10.1210/endo.136.10.7664679 · doi:10.1210/endo.136.10.7664679 · Paper page
- 1992, Endocrinology., 131, 1497, 10.1210/endo.131.3.1324163 · doi:10.1210/endo.131.3.1324163 · Paper page
- 1987, Am. J. Pathol., 127, 414
Cited by
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
“By contrast, mice deficient in amylin, another related peptide from the calcitonin gene superfamily, show osteopeni”
BackgroundOsteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 659
Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery
Kovacs, C. S. (2016) · Physiological Reviews · doi:10.1152/physrev.00027.2015 · Cited by 544
Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis
Zhao, L.-J., Jiang, H., Papasian, C. J., Maulik, D., Drees, B., Hamilton, J., & Deng, H.-W. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070813 · Cited by 528
“reduce osteoclast development and thus inhibit bone resorption.((157)) In addition, amylin stimulates the prolifera-”
BackgroundOsteoporosis in Patients With Diabetes Mellitus
Hofbauer, L. C., Brueck, C. C., Singh, S. K., & Dobnig, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070510 · Cited by 503
“The phenotype of amylin-deficient mice is characterized by osteopenia and enhanced bone resorption, and amylin was found to inhibit osteoclastogenesis in vitro.((34))”
Background
Metadata
- Authors
- Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G.
- Affiliations
- Baylor College of Medicine (US)
- The University of Melbourne (AU)
- Beth Israel Deaconess Medical Center (US)
- 1Department of Molecular and Human Genetics and Bone Disease Program of Texas, Baylor College of Medicine, Houston, TX 77030
- Hanson Institute (AU)
- 5Department of Clinical Genetics, Lund University Hospital, SE-221 85, Lund, Sweden
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2004-02-16
- Volume
- 164
- Issue
- 4
- Pages
- 509-514
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2171986
- OpenAlex
- W2108642017
- Semantic Scholar
- 435fe5512c7d1d24870030fa33708cac75f27d06
- Cited by
- 206
- References
- 25
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 5 · 2016: 7 · 2015: 10 · 2014: 12 · 2013: 7 · 2012: 11
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Cell Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058883, R01-DK58883)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR45421, R01AR045421)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
- Keywords
- amylin, calcitonin receptor, bone resorption, bone formation, osteoclastogenesis, osteoclast precursors, ERK signaling, osteopenia, bone metabolism regulation
- MeSH terms
- Amyloid, Animals, Bone and Bones, Bone Resorption, Cell Differentiation, Mice, Inbred C57BL, Osteoclasts, Osteogenesis, Phenotype, Bone Density, Receptors, Calcitonin, Mice, Knockout, Mitogen-Activated Protein Kinases, Mice, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. https://app.cochat.ai/papers/10.1083/jcb.200312135
- The paper
- Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G. (2004). Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. The Journal of Cell Biology. https://doi.org/10.1083/jcb.200312135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.